S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
The Day of Financial Reckoning Is Near (Ad)
Climate bill: Could coal communities shift to nuclear?
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
High oil prices help Saudi Aramco earn $88B in first half
The Day of Financial Reckoning Is Near (Ad)
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi Aramco's profits already $88B as oil prices stay high
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
The Day of Financial Reckoning Is Near (Ad)
Climate bill: Could coal communities shift to nuclear?
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
High oil prices help Saudi Aramco earn $88B in first half
The Day of Financial Reckoning Is Near (Ad)
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi Aramco's profits already $88B as oil prices stay high
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
The Day of Financial Reckoning Is Near (Ad)
Climate bill: Could coal communities shift to nuclear?
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
High oil prices help Saudi Aramco earn $88B in first half
The Day of Financial Reckoning Is Near (Ad)
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi Aramco's profits already $88B as oil prices stay high
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
The Day of Financial Reckoning Is Near (Ad)
Climate bill: Could coal communities shift to nuclear?
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
High oil prices help Saudi Aramco earn $88B in first half
The Day of Financial Reckoning Is Near (Ad)
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi Aramco's profits already $88B as oil prices stay high
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
OTCMKTS:PBSV

Pharma-Bio Serv - PBSV Stock Forecast, Price & News

$0.75
+0.10 (+15.38%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.74
$0.75
50-Day Range
$0.61
$0.96
52-Week Range
$0.58
$1.17
Volume
4,600 shs
Average Volume
2,043 shs
Market Capitalization
$17.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
PBSV stock logo

About Pharma-Bio Serv (OTCMKTS:PBSV) Stock

Pharma-Bio Serv, Inc. operates as a compliance and technology transfer services consulting firm. The company provides compliance consulting services to the pharmaceutical, chemical, biotechnology, medical device, cosmetic, food industries, and allied products companies in Puerto Rico, the United States, Europe, and Brazil. Its technical consulting services comprise regulatory compliance, validation, technology transfer, engineering, project management, and process support. The company was founded in 1993 and is headquartered in Dorado, Puerto Rico.

Receive PBSV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pharma-Bio Serv and its competitors with MarketBeat's FREE daily newsletter.

PBSV Stock News Headlines

Brazil's Biolab buys Canada's Exzell Pharma
Expert Ratings for Biomarin Pharmaceutical
PBSV: Lowering target; still a solid value
Pharma-Bio Serv reports Q2 results
What 4 Analyst Ratings Have To Say About Biomarin Pharmaceutical
PBSV: Steady As She Goes
Pharma-Bio Serv declares $0.075 special dividend
Pharma-Bio Serv Inc (PBSV)
Pharma-Bio Serv, Inc. (PBSV)
PBSV: Restarts Repurchase Plan
PBSV: New model, raising target
See More Headlines
Receive PBSV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pharma-Bio Serv and its competitors with MarketBeat's FREE daily newsletter.

PBSV Company Calendar

Today
8/14/2022
Fiscal Year End
10/31/2022

Industry, Sector and Symbol

Industry
Management consulting services
Sub-Industry
N/A
Current Symbol
OTCMKTS:PBSV
Employees
190
Year Founded
N/A

Profitability

Net Income
$-2,090,000.00
Pretax Margin
-8.96%

Debt

Sales & Book Value

Annual Sales
$20.11 million
Book Value
$0.81 per share

Miscellaneous

Free Float
20,526,000
Market Cap
$17.60 million
Optionable
Not Optionable
Beta
0.36

Key Executives

  • Mr. Victor Sanchez (Age 51)
    CEO, Pres & Pres of European Operations
    Comp: $346.55k
  • Ms. Elizabeth Plaza (Age 58)
    Founder & Sr. Strategic Consultant
    Comp: $69.92k
  • Mr. Pedro J. Lasanta (Age 62)
    CFO, VP of Fin. & Admin. and Sec.
    Comp: $250.6k
  • Ms. Miriam Marrero M.B.A.
    HR Mang.













PBSV Stock - Frequently Asked Questions

How have PBSV shares performed in 2022?

Pharma-Bio Serv's stock was trading at $1.03 on January 1st, 2022. Since then, PBSV shares have decreased by 27.2% and is now trading at $0.75.
View the best growth stocks for 2022 here
.

How often does Pharma-Bio Serv pay dividends? What is the dividend yield for Pharma-Bio Serv?

Pharma-Bio Serv declared a dividend on Friday, February 18th. Investors of record on Friday, February 25th will be paid a dividend of $0.075 per share on Tuesday, March 15th. This represents a yield of 16.13%. The ex-dividend date is Thursday, February 24th.
Read our dividend analysis for PBSV
.

What other stocks do shareholders of Pharma-Bio Serv own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pharma-Bio Serv investors own include Zynerba Pharmaceuticals (ZYNE), Allena Pharmaceuticals (ALNA), AstroNova (ALOT), Oracle (ORCL), AT&T (T), Yintech Investment (YIN), Aeglea BioTherapeutics (AGLE), Ampliphi Biosciences (APHB), Carnival Co. & (CCL) and Earthstone Energy (ESTE).

What is Pharma-Bio Serv's stock symbol?

Pharma-Bio Serv trades on the OTCMKTS under the ticker symbol "PBSV."

How do I buy shares of Pharma-Bio Serv?

Shares of PBSV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pharma-Bio Serv's stock price today?

One share of PBSV stock can currently be purchased for approximately $0.75.

How much money does Pharma-Bio Serv make?

Pharma-Bio Serv (OTCMKTS:PBSV) has a market capitalization of $17.60 million and generates $20.11 million in revenue each year. The company earns $-2,090,000.00 in net income (profit) each year or ($0.09) on an earnings per share basis.

How many employees does Pharma-Bio Serv have?

The company employs 190 workers across the globe.

How can I contact Pharma-Bio Serv?

Pharma-Bio Serv's mailing address is Pharma-Bio Serv Building Suite 6 Road 696, DORADO PR, 00646. The official website for the company is www.pharmabioserv.com. The company can be reached via phone at (787) 278-2709, via email at scottg@corprominence.com, or via fax at 787-796-5168.

This page (OTCMKTS:PBSV) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.